<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088785</url>
  </required_header>
  <id_info>
    <org_study_id>NL76658.029.21</org_study_id>
    <nct_id>NCT05088785</nct_id>
  </id_info>
  <brief_title>Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer</brief_title>
  <acronym>FEStastic</acronym>
  <official_title>Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      16a-18F-fluoro-17b-estradiol ([18F]FES) is radioactive labeled estradiol, developed for in&#xD;
      vivo visualization of the estrogen receptor (ER) using positron emission tomography (PET). To&#xD;
      date, [18F]FES PET has been mainly explored as a diagnostic imaging tool to assess ER&#xD;
      expression, thereby identifying locations of disease and their potential sensitivity to&#xD;
      endocrine therapy, respectively. The primary aim of this project is to extend the application&#xD;
      of [18F]FES PET as a baseline diagnostic imaging biomarker for ER expression to use it as an&#xD;
      (early) treatment response marker. However, for such an application, visual assessment alone&#xD;
      may not be sufficient and a more rigorous quantitative image analysis is needed. Therefore,&#xD;
      in this project we shall first derive the optimal pharmacokinetic model for full quantitative&#xD;
      analysis of [18F]FES uptake and, subsequently, we shall assess the validity of simplified,&#xD;
      clinically feasible, quantitative parameters of [18F]FES uptake in 5 patients with metastatic&#xD;
      estrogen receptor positive (ER+) breast cancer (part A). In addition, the repeatability of&#xD;
      these simplified parameters will then be investigated in another 10 patients (part B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">April 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FES uptake in lesions: Ki (net influx rate) or VT (volume of distribution) values</measure>
    <time_frame>1 year</time_frame>
    <description>FES uptake in lesions will be expressed as Ki or VT values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SUV and TBR values</measure>
    <time_frame>1 year.</time_frame>
    <description>Quantification of FES uptake in lesions will be assessed by determining standardized uptake values and tumor-to-blood ratios.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SUV and TBR values</measure>
    <time_frame>1 year.</time_frame>
    <description>Repeatability of standardized uptake values and tumor-to-blood ratios will be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: dynamic FES PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients included in part A will receive a dynamic FES PET/CT scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: whole body static FES PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients included in part B will receive a whole body static FES PET/CT scan twice within 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FES</intervention_name>
    <description>[18F]FES PET imaging.</description>
    <arm_group_label>Part A: dynamic FES PET imaging</arm_group_label>
    <arm_group_label>Part B: whole body static FES PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven metastatic ER+ (&gt;10% positive stained cells using&#xD;
             immunohistochemistry) breast cancer on the latest biopsy&#xD;
&#xD;
          -  Postmenopausal females aged 18 years or older at screening. Postmenopausal status is&#xD;
             defined as one of the following:&#xD;
&#xD;
               1. age ≥60 years&#xD;
&#xD;
               2. age &lt;60 years and amenorrhea for &gt;12 months in the absence of interfering&#xD;
                  hormonal therapies (such as LH-RH agonists and ER-antagonists)&#xD;
&#xD;
               3. patient age &lt;60 years using LH-RH agonists should continue LH- RH-agonists until&#xD;
                  after the PET procedures&#xD;
&#xD;
               4. previous bilateral oophorectomy or medically confirmed ovarian failure&#xD;
&#xD;
          -  [18F]FDG PET, CT and/or a bone scan should be performed as part of routine clinical&#xD;
             staging (≤4 weeks prior to screening)&#xD;
&#xD;
          -  Patients should have metastases in the scanning field of view, all located outside of&#xD;
             the liver&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥30 ml/min&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History with another cancer within the last 5 years, except cancer treated with&#xD;
             curative intent and no evidence of disease as judged by the treating physician&#xD;
&#xD;
          -  Use of selective estrogen receptor modulators (SERMs) or downregulators (SERDs) for&#xD;
             current breast cancer such as Tamoxifen/Fulvestrant (≤5 weeks prior to screening) or&#xD;
             investigational drug therapy&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Any medical, psychological or social condition that may interfere with the subject's&#xD;
             safety and participation in the study, will lead to exclusion from this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherina W Menke-van der Houven van Oordt, MD PhD</last_name>
    <phone>+31 (0)20 4444 773</phone>
    <email>dm-onco@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Data-management Medical Oncology</last_name>
    <phone>+31 (0)20 4444 773</phone>
    <email>dm-onco@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam UMC - location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramsha Iqbal, MD</last_name>
      <email>r.iqbal@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ramsha Iqbal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>C. Menke- van der Houven van Oordt</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

